Skip to main content
. 2018 Jul 5;103(10):1720–1729. doi: 10.3324/haematol.2017.187385

Figure 6.

Figure 6.

CD16+NK-92 in vitro ADCC assay against primary acute myeloid leukemia (AML) and OCI/AML5. OCI/AML5 cells were labeled with 100 μCi of Na251CrO4 for 2 hours +/− 10 μg/mL of 7G3 (anti-CD123 mAb) prior to treatment with CD16+NK-92 in 96-well plates in a standard chromium release assay. Data are presented as the mean percent lysis of triplicate samples (+/−Standard Deviation) from a representative experiment carried out twice.